Ruff, Andrew
Ballard, Hatcher J.
Pantel, Austin R.
Namoglu, Esin C.
Hughes, Mitchell E.
Nasta, Sunita D.
Chong, Elise A.
Bagg, Adam
Ruella, Marco
Farwell, Michael D.
Svoboda, Jakub
Sellmyer, Mark A. http://orcid.org/0000-0002-1407-1905
Funding for this research was provided by:
NIH Office of the Director (DP5-OD26386)
Burroughs Wellcome Fund (CAMS)
Article History
Received: 29 January 2021
Revised: 9 June 2021
Accepted: 16 June 2021
First Online: 6 July 2021
Declarations
:
: AR: none. HJB: none. ARP: none. ECN: none. MEH: AstraZeneca, Genzyme, Janssen, AbbVie: consultancy; Acerta Pharma, HOPA: research Support. SDN: Roche, Rafael, Forty Seven, Pharmacyclics, Incyte, Debiopharm, Aileron: research support; Morphosys: honorarium. EAC: Novartis, BMS, KITE: advisory boards. AB: none. MR: BMS, NanoString: consultancy; UPenn/Novartis: patents and royalties; Abclon: consultancy, research funding. MDF: none. JS: Genmab, Adaptive, Imbrium, Atara: consultancy; Incyte, Merck: research funding; AstraZeneca, BMS, Pharmacyclics, Seattle Genetics: consultancy, research funding; TG: research funding. MAS: co-founder of Vellum Biosciences, which is supporting the development and commercialization of radiotracers to monitor gene and cell therapies.